Lipella Pharmaceuticals Inc. (LIPO)

Lipella Pharmaceuticals Earnings Call Transcripts

Fiscal Year 2025

• Life Sciences Virtual Investor Forum 2025

  Proprietary liposomal technology enables targeted delivery for mucosal diseases, with LP-10 oral rinse showing strong safety and efficacy in phase two OLP trials. Addressing a significant unmet need, LP-10 targets a $750M peak sales opportunity, with next steps including a placebo-controlled trial and industry partnership.

  Read full transcript →

Data Source: Quartr Last updated: Sep 18, 2025

Earnings call transcripts are provided by Quartr and are published within hours after each earnings call.

Update frequency:

Quarterly

Data Sources Report a data error

Stock Analysis Pro

Upgrade now for unlimited access to all data and tools.

Market Newsletter

Get a daily email with the top market news in bullet point format.